Precigen’s Financial Crossroads: Can New Funding and FDA Approval Steer a Turnaround?

Q2 2025 Results Sound Alarm Bells

While Precigen recently secured a $125 million credit facility and gained full FDA approval for its flagship product, AdenoVerse PRZIME (previously referred to as PAPZIMEOS), its latest quarterly earnings reveal a company in a precarious financial position. The stark contrast between these developments paints a complex picture for the biotechnology firm.